dclk1

LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.

LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.

DCLK1-IN-3 is a potent and selective inhibitor of doublecortin-like kinase 1 (DCLK1) with an IC50 of 47 nM, and it is applicable in cancer research.

DCLK1-IN-4 (compound D2) is a potent and selective inhibitor of doublecortin-like kinase 1 (DCLK1), with an IC50 of 70 nM. It is applicable to cancer research.

DCLK1-IN-2 (Compound I-5) is a potent inhibitor of DCLK1, exhibiting an IC50 of 171.3 nM, and demonstrates significant antiproliferative effects on SW1990 cell lines with an IC50 of 0.6 μM, as well as in vivo antitumor potency [1].

DCLK1-IN-1 is a selective, in vivo compatible chemical probe of the kinase domain of doublecortin-like kinase 1 (DCLK1) and a highly selective DCLK1/2 inhibitor with IC50 values ​​of 9.5/57.2 nM (DCLK1) and 31/103 nM (DCLK2) by binding and kinase assays, respectively. It has low toxicity and is used to study DCLK1 biology and determine its role in cancer.

DCLK1-IN-5 (Compound a24), with an IC 50 of 179.7 nM, acts as a DCLK1 inhibitor. It mitigates lipopolysaccharide-induced inflammation by blocking DCLK1-mediated IKKβ phosphorylation. Additionally, DCLK1-IN-5 offers protection to mice from lung injuries and sepsis caused by inflammation [1].

XMD-17-51 has DCLK1 kinase inhibitory activity, inhibits DCLK1 and cell proliferation, and can be used in lung cancer research.